Trends in clinical trials for olfactory dysfunction in the COVID-19 era

Vickie J Wang; Hisham Abdou; Amar H Sheth; R Peter Manes; Ryan Rimmer

doi:10.1002/alr.23144

Trends in clinical trials for olfactory dysfunction in the COVID-19 era

Int Forum Allergy Rhinol. 2023 Oct;13(10):1958-1961. doi: 10.1002/alr.23144. Epub 2023 Mar 15.

Authors

Vickie J Wang¹, Hisham Abdou¹, Amar H Sheth¹, R Peter Manes², Ryan Rimmer²

Affiliations

¹ Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Surgery (Otolaryngology), Yale School of Medicine, New Haven, Connecticut, USA.

PMID: 36851905
DOI: 10.1002/alr.23144

Abstract

Nearly half of all olfactory dysfunction (OD) clinical trials since 2010 are COVID-19-related. COVID-19-related OD trials are published significantly faster than COVID-19-unrelated trials. High-quality clinical trials and publications are crucial to discovering effective treatments.

Keywords: COVID-19; meta-research; olfactory impairment; post-COVID conditions.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Humans
Olfaction Disorders* / epidemiology
Olfaction Disorders* / therapy
SARS-CoV-2
Smell